Globus Medical EBIT

The latest EBIT for GMED is $650M as of March 2026. That compares with $170M in the prior-year period — up 286.9% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Globus Medical's historical trend and sector peers before judging valuation or financial health.

Over the past year, GMED's EBIT moved from $170M to $650M — a 286.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Globus Medical's operating scale or balance-sheet position.

Against Healthcare companies, GMED currently prints $650M for EBIT, while the sector average sits near $23B. That is roughly 97.2% below the sector mean. Large gaps often invite a closer look at Globus Medical's growth, margins, and balance sheet.

A EBIT figure of $650M for GMED is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting GMED's EBIT ($650M), review year-over-year change from $170M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.